Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 4 Other neoplasm 1 Other hematologic neoplasm 1 Lymphoid 1 Genitourinary 1 Gastrointestinal 1 Breast 1

Conditions

Interventions

Rituximab 377 Cyclophosphamide 180 Bendamustine Hydrochloride 110 obinutuzumab 100 Vincristine 95 fludarabine 92 Prednisone 90 Doxorubicin 90 ibrutinib 89 venetoclax 86 Lenalidomide 82 Gemcitabine 65 acalabrutinib 48 Brentuximab Vedotin 44 pembrolizumab 43 zanubrutinib 41 Dexamethasone 41 idelalisib 37 ofatumumab 32 Oxaliplatin 30 Chlorambucil 29 polatuzumab vedotin 25 blinatumomab 25 tocilizumab 24 Azacitidine 24 Prednisolone 23 tositumomab I-131 22 tisagenlecleucel 21 glofitamab 21 Nivolumab 21

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × tirbanibulin × Lymphoid × Clear all

NCT00658970 2011-06-08

Evaluation of KX2-391 in Patients With Advanced Malignancies

Athenex, Inc.

Phase 1 Completed

Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡